Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Charles River, AstraZeneca in Strategic Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Charles River, AstraZeneca in Strategic Partnership

Three-year pact covers safety assessment, development DMPK

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AstraZeneca has selected Charles River Laboratories International as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics). The three-year agreement extends into 2015. AZ began the process of transferring programs to Charles River earlier this year. This process is expected to be completed by early 2013. Terms were not disclosed, but CRL reported that incremental sales under this agreement are expected to contribute approximately 1% to Charles River’s total net sales in 2013.

James C. Foster, chairman, president and chief executive officer of Charles River, commented, “We are extremely pleased that AstraZeneca selected Charles River as its strategic in vivo biology partner. Utilizing our capabilities will enable AstraZeneca to create a flexible research platform to deliver innovative health solutions. Our shared passion for scientific excellence is a strong foundation for this relationship, and we look forward to working with AstraZeneca’s scientists ‘on the same side of the table’ to achieve their drug development goals.”

Stefan Platz, vice president, Global Safety Assessment, AstraZeneca, added, “Tapping into the high-quality drug development services of a trusted strategic partner enables AstraZeneca to increase our resource flexibility while simplifying the way we work. We are pleased to partner with Charles River to utilize their scientific expertise, such as their customized in vivo biology program. Our organizations will work hand-in-hand to deliver toxicology, safety pharmacology and development DMPK studies in support of our efforts to deliver safe and effective new treatments to patients more efficiently.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics